
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
TrialScope has released results from its 2nd Biennial Plain Language Summaries Survey. The top factors driving sponsors to provide plain language summaries are regulatory requirements, evolving transparency trends and patient engagement initiatives.
To find more of the survey’s findings, click







